Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Conditions:   Non-small Cell Lung Cancer;   IIIb/IIIc/IV;   First-line Treatment Interventions:   Biological: CIK cell;   Biological: IBI308;   Drug: Pemetrexed;   Drug: Gemcitabine;   Drug: Carboplatin Sponsor:   Tianjin Medical University Cancer Institute and Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials